|
1. Biologie
|
|
|
JAX Researchers Reveal Genomic Culprit, Treatment Strategy for Some Deadly Cancers [JAX]
|
|
|
|
|
|
A
research team led by Jackson Laboratory (JAX) President and CEO Edison
Liu, M.D., has found a molecular fingerprint of some of the most deadly
cancers of women: a genomic configuration described as a tandem
duplicator phenotype (TDP) that is significantly enriched in
triple-negative breast cancer, serous ovarian cancer and endometrial
carcinomas, and that responds to a specific chemotherapy.
|
|
|
|
|
|
|
3. Prévention
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Making the Price Right: Ideas To Change Drug Costs Gain Momentum [Xconomy]
|
|
|
|
|
|
Lo
and Weinstock want to convene a conference this fall to flesh out the
loan idea. Whether their brainchild actually grows into a loan program
or not, elements of it are common to many of the creative ideas now in
play, so the conversation should be welcome. For many, the question
isn’t if changes are coming, it’s when.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.4 Médico-éco
|
|
|
Patients Miss Out On Savings When Doctors Fail To Talk About Costs [NPR]
|
|
|
|
|
|
The
researchers analyzed transcripts of almost 2,000 physician-patient
conversations regarding breast cancer, rheumatoid arthritis and
depression treatment. They identified instances in which patients
suggested the cost of care might be difficult for them to bear and
assessed how doctors responded.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
ORCID: what, why, how? [BioMed Central blog]
|
|
|
|
|
|
If
you’re a researcher or work in a research organization, the chances are
that over the past couple of years you’ve started to hear about ORCID.
Maybe you’re one of the over 2million people who have already signed up
for an ORCID iD, or you know colleagues who have.
|
|
|
|
|
|
|
|
|
6.7.2 Applis
|
|
|